[1. Sarafoleanu D. Tumorile maligne ale laringelui. In: Sarafoleanu C, editor. Esenţialul in laringologie. Editura Academiei Romane. Bucuresti. 2007. p. 322–351.]Search in Google Scholar
[2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008 Jul 24;454(7203):436–44. DOI: 10.1038/nature0720510.1038/nature0720518650914]Search in Google Scholar
[3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–74. DOI: 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.01321376230]Search in Google Scholar
[4. Peltanova B, Raudenska M, Masarik M. Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. Molecular Cancer. 2019 Mar 30;18(1):63. DOI: 10.1186/s12943-019-0983-510.1186/s12943-019-0983-5644117330927923]Search in Google Scholar
[5. Barnes L, Tse LLY, Hunt Jl, Brandwein-Gensler M, Urken M, Slootwef P, et al. Tumours of the hypopharynx, larynx and trachea: Introduction. In: Barnes L, Evenson JW, Reichart P, Sidransky D, editors. World Health Classification of Tumors Pathology and Genetics of Head and Neck Tumors. IARC Press. Lyon. 2005. p.109–120.]Search in Google Scholar
[6. Armstrong WB, Vokes DE, Verma SP. Malignant tumors of the larynx. In: Flint PW, Haughey BH, Lund V, Niparko JK, Robbins KT, Thomas JR, Lesperance MM, editors. Cummings Otolaryngology Head and Neck surgery. Sixth Edition. Elsevier. Philadelphia. 2014. p.1880–1923.]Search in Google Scholar
[7. Akira S, Uematsu S, Takeuchi O. Pathogen Recognition and Innate Immunity. Cell. 2006 Feb 24;124(4):783–801. DOI: 10.1016/j.cell.2006.02.01510.1016/j.cell.2006.02.01516497588]Search in Google Scholar
[8. Ferwerda B, McCall MB, Verheijen K, Kullberg B-J, van der Ven AJ, Van der Meer JW, et al. Functional Consequences of Toll-like Receptor 4 Polymorphisms. Mol Med. 2008;14(5–6):346–52. DOI: 10.2119/2007-00135.Ferwerda10.2119/2007-00135.Ferwerda221576518231573]Search in Google Scholar
[9. Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol. 2011;2011:609579. DOI: 10.1155/2011/60957910.1155/2011/609579321629222110526]Search in Google Scholar
[10. Sato Y, Goto Y, Narita N, Hoon DSB. Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron. 2009 Aug 15;2(Suppl 1):205–14. DOI: 10.1007/s12307-009-0022-y10.1007/s12307-009-0022-y275633919685283]Search in Google Scholar
[11. Mai CW, Kang YB, Pichika MR. Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Onco Targets Ther. 2013 Nov 5;6:1573–87. DOI: 10.2147/OTT.S5083810.2147/OTT.S50838382179224235843]Search in Google Scholar
[12. Zhu L, Yuan H, Jiang T, Wang R, Ma H, Zhang S. Association of TLR2 and TLR4 Polymorphisms with Risk of Cancer: A Meta-Analysis. PLOS ONE. 2013 Dec 20;8(12):e82858. DOI: 10.1371/journal.pone.008285810.1371/journal.pone.0082858386972324376595]Search in Google Scholar
[13. Sancar A. Mechanisms of DNA excision repair. Science. 1994 Dec 23;266(5193):1954–6. DOI: 10.1126/science.780112010.1126/science.78011207801120]Search in Google Scholar
[14. Torgovnick A, Schumacher B. DNA repair mechanisms in cancer development and therapy. Front Genet. 2015; 6: 157 DOI: 10.3389/fgene.2015.0015710.3389/fgene.2015.00157]Search in Google Scholar
[15. Berwick M, Vineis P. Markers of DNA Repair and Susceptibility to Cancer in Humans: an Epidemiologic Review. J Natl Cancer Inst. 2000 Jun 7;92(11):874–97. DOI: 10.1093/jnci/92.11.87410.1093/jnci/92.11.874]Search in Google Scholar
[16. Caldecott KW, Aoufouchi S, Johnson P, Shall S. XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular “nick-sensor” in vitro. Nucleic Acids Res. 1996 Nov 15;24(22):4387–94. DOI: 10.1093/nar/24.22.438710.1093/nar/24.22.4387]Search in Google Scholar
[17. Khlifi R, Rebai A, Hamza-Chaffai A. Polymorphisms in human DNA repair genes and head and neck squamous cell carcinoma. J Genet. 2012 Dec 1;91(3):375–84. DOI: 10.1007/s12041-012-0193-z10.1007/s12041-012-0193-z]Search in Google Scholar
[18. Wang M, Chu H, Zhang Z, Wei Q. Molecular epidemiology of DNA repair gene polymorphisms and head and neck cancer. J Biomed Res. 2013 May;27(3):179–92.]Search in Google Scholar
[19. Feng YZ, Liu YL, He XF, Wei W, Shen XL, Xie DL. Association between the XRCC1 Arg194Trp polymorphism and risk of cancer: evidence from 201 case-control studies. Tumor Biol. 2014 Nov 1;35(11):10677–97. DOI: 10.1007/s13277-014-2326-x10.1007/s13277-014-2326-x]Search in Google Scholar
[20. Yi L, Xiao-feng H, Yun-tao L, Hao L, Ye S, Song-tao Q. Association between the XRCC1 Arg399Gln Polymorphism and Risk of Cancer: Evidence from 297 Case-Control Studies. PLOS ONE. 2013;8(10):e78071. DOI: 10.1371/journal.pone.007807110.1371/journal.pone.0078071]Search in Google Scholar
[21. Schultz P, Fribourg S, Poterszman A, Mallouh V, Moras D, Egly JM. Molecular Structure of Human TFIIH. Cell. 2000 Sep 1;102(5):599–607. DOI: 10.1016/S0092-8674(00)00082-910.1016/S0092-8674(00)00082-9]Search in Google Scholar
[22. Chen J, Suter B. Xpd, a Structural Bridge and a Functional Link. Cell Cycle. 2003 Nov 28;2(6):503–6. DOI: 10.4161/cc.2.6.55810.4161/cc.2.6.55814504460]Search in Google Scholar
[23. Fan L, Fuss JO, Cheng QJ, Arvai AS, Hammel M, Roberts VA, et al. XPD Helicase Structures and Activities: Insights into the Cancer and Aging Phenotypes from XPD Mutations. Cell. 2008 May 30;133(5):789–800. DOI: 10.1016/j.cell.2008.04.03010.1016/j.cell.2008.04.030305524718510924]Search in Google Scholar
[24. Coin F, Marinoni J-C, Rodolfo C, Fribourg S, Pedrini AM, Egly J-M. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat Genet. 1998 Oct;20(2):184–8. DOI: 10.1038/249110.1038/24919771713]Search in Google Scholar
[25. Mitra AK, Singh N, Garg VK, Chaturvedi R, Sharma M, Rath SK. Statistically significant association of the single nucleotide polymorphism (SNP) rs13181 (ERCC2) with predisposition to Squamous Cell Carcinomas of the Head and Neck (SCCHN) and Breast cancer in the north Indian population. J Exp Clin Cancer Res. 2009 Jul 18;28(1):104. DOI: 10.1186/1756-9966-28-10410.1186/1756-9966-28-104272438919615095]Search in Google Scholar
[26. Fu W, Xiao F, Zhang R, Li J, Zhao D, Lin X, et al. Association Between the Asp312Asn, Lys751Gln, and Arg156Arg Polymorphisms in XPD and the Risk of Prostate Cancer. Technol Cancer Res Treat. 2017 Dec;16(6):692–704. DOI: 10.1177/153303461772467810.1177/1533034617724678576207228797198]Search in Google Scholar
[27. Yin J, Vogel U, Ma Y, Guo L, Wang H, Qi R. Polymorphism of the DNA repair gene ERCC2 Lys751Gln and risk of lung cancer in a northeastern Chinese population. Cancer Genetics and Cytogenetics. 2006 Aug 1;169(1):27–32. DOI: 10.1016/j.cancergencyto.2006.03.00810.1016/j.cancergencyto.2006.03.00816875933]Search in Google Scholar
[28. Procopciuc LM, Osian G. Interaction between lifestyle factors and the XRCC1, XPD, and XRCC3 genetic variations modulates the risk for sporadic colorectal cancer. Revista Romana de Medicina de Laborator. 2014 Mar 1;22(1):129–41. DOI: 10.2478/rrlm-2014-000210.2478/rrlm-2014-0002]Search in Google Scholar
[29. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013 Nov 27;310(20):2191–4. DOI: 10.1001/jama.2013.28105310.1001/jama.2013.28105324141714]Search in Google Scholar
[30. de Miguel-Luken MJ, Chaves-Conde M, Carnero A. A genetic view of laryngeal cancer heterogeneity. Cell Cycle. 2016 Mar 3;15(9):1202–12. DOI: 10.1080/15384101.2016.115627510.1080/15384101.2016.1156275489450526940775]Search in Google Scholar
[31. Szczepański M, Stelmachowska M, Stryczyński L, Golusiński W, Samara H, Mozer-Lisewska I, et al. Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur Arch Otorhinolaryngol. 2007 May;264(5):525–30. DOI: 10.1007/s00405-006-0215-710.1007/s00405-006-0215-717165086]Search in Google Scholar
[32. Sikora J, Frydrychowicz M, Kaczmarek M, Brzezicha B, Mozer-Lisewska I, Szczepański M, et al. TLR receptors in laryngeal carcinoma - immunophenotypic, molecular and functional studies. Folia Histochemica et Cytobiologica. 2010 Dec 1;48(4):624–31. DOI: 10.2478/v10042-010-0077-010.2478/v10042-010-0077-021478107]Search in Google Scholar
[33. Bergmann C, Bachmann HS, Bankfalvi A, Lotfi R, Pütter C, Wild CA, et al. Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J Transl Med. 2011 Aug 21;9:139. DOI: 10.1186/1479-5876-9-13910.1186/1479-5876-9-139317060321854645]Search in Google Scholar
[34. Ding L, Jiang Q, Li G, Shen J, Du J, Lu X, et al. Comprehensive assessment of association between TLR4 gene polymorphisms and cancer risk: a systematic meta-analysis. Oncotarget. 2017 Nov 21;8(59):100593–602. DOI: 10.18632/oncotarget.2154310.18632/oncotarget.21543572504629246004]Search in Google Scholar
[35. Alimu N, Qukuerhan A, Wang S, Abdurehim Y, Kuyaxi P, Zhang B, et al. The association between XRCC1 polymorphism and laryngeal cancer susceptibility in different ethnic groups in Xinjiang, China. Int J Clin Exp Pathol. 2018 Sep 1;11(9):4595–604.]Search in Google Scholar
[36. Li F, Wang J, Chen M. Single nucleotide polymorphisms in DNA repair genes and the risk of laryngeal cancer: A meta-analysis. Biomedicine & Pharmacotherapy. 2016 Mar 1;78:92–100. DOI: 10.1016/j.biopha.2015.12.01910.1016/j.biopha.2015.12.019]Search in Google Scholar
[37. Olshan AF, Watson MA, Weissler MC, Bell DA. XRCC1 polymorphisms and head and neck cancer. Cancer Lett. 2002;178:181–6 DOI: 10.1016/S0304-3835(01)00822-910.1016/S0304-3835(01)00822-9]Search in Google Scholar
[38. Huang W-Y, Olshan AF, Schwartz SM, Berndt SI, Chen C, Llaca V, et al. Selected Genetic Polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and Risk of Head and Neck Cancer: A Pooled Analysis. Cancer Epidemiol Biomarkers Prev. 2005 Jul 1;14(7):1747–53. DOI: 10.1158/1055-9965.EPI-05-016210.1158/1055-9965.EPI-05-016216030112]Search in Google Scholar
[39. Hu Z, Ma H, Chen F, Wei Q, Shen H. XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1810–1818 DOI: 10.1158/1055-9965.EPI-04-079310.1158/1055-9965.EPI-04-079316030121]Search in Google Scholar
[40. Varzim G, Monteiro E, Silva RA, Fernandes J, Lopes C. CYP1A1 and XRCC1 gene polymorphisms in SCC of the larynx. Eur J of Cancer Prev. 2003 Dec;12(6):495–9. DOI: 10.1097/00008469-200312000-0000810.1097/00008469-200312000-0000814639127]Search in Google Scholar
[41. Chen W, Wang ZY, Xu FL, Wu KM, Zhang Y, Xu L, et al. Association of XRCC1 genetic polymorphism (Arg399Gln) with laryngeal cancer: a meta-analysis based on 4,031 subjects. Tumor Biol. 2014 Feb 1;35(2):1637–40. DOI: 10.1007/s13277-013-1225-x10.1007/s13277-013-1225-x24194393]Search in Google Scholar
[42. Wu WQ, Zhang LS, Liao SP, Lin XL, Zeng J, Du D. Association between XRCC1 polymorphisms and laryngeal cancer susceptibility in a Chinese sample population. Genet Mol Res. 2016 Oct 5;15(4). DOI: 10.4238/gmr.1504852510.4238/gmr.1504852527808358]Search in Google Scholar
[43. Yuan H, Li H, Ma H, Niu Y, Wu Y, Zhang S, et al. Genetic polymorphisms in key DNA repair genes and risk of head and neck cancer in a Chinese population. Exp Ther Med. 2012 Apr;3(4):719–24. DOI: 10.3892/etm.2012.47610.3892/etm.2012.476343858622969958]Search in Google Scholar
[44. Wu W, Liu L, Yin Z, Guan P, Li X, Zhou B. Association of X-Ray Repair Cross-Complementing Group 1 Arg194Trp, Arg399Gln and Arg280His Polymorphisms with Head and Neck Cancer Susceptibility: A Meta-Analysis. PLOS ONE. 2014;9(1):e86798. DOI: 10.1371/journal.pone.008679810.1371/journal.pone.0086798390744624497981]Search in Google Scholar
[45. Lou Y, Peng W, Cao D, Xie J, Li H, Jiang Z. DNA Repair Gene XRCC1 Polymorphisms and Head and Neck Cancer Risk: An Updated Meta-Analysis Including 16344 Subjects. PLOS ONE. 2013 Sep 23;8(9):e74059. DOI: 10.1371/journal.pone.007405910.1371/journal.pone.0074059378116824086310]Search in Google Scholar
[46. Lin H, Lin D, Zheng C. Association of XPD Lys751Gln polymorphism with head and neck cancer susceptibility: evidence from 11,443 subjects. Diagn Pathol. 2014 Jan 20;9:15. DOI: 10.1186/1746-1596-9-1510.1186/1746-1596-9-15391608124443924]Search in Google Scholar
[47. Yuan H, Niu YM, Wang RX, Li HZ, Chen N. Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis. Genet Mol Res. 2011;10(4):3356–64 DOI: 10.4238/2011.November.22.610.4238/2011.November.22.622179996]Search in Google Scholar
[48. Hou S-M, Ryk C, Kannio A, Angelini S, Fält S, Nyberg F, et al. Influence of common XPD and XRCC1 variant alleles on p53 mutations in lung tumors. Environmental and molecular mutagenesis. 2003 Feb 1;41:37–42. DOI: 10.1002/em.1012810.1002/em.1012812552590]Search in Google Scholar
[49. Zhong S, Nukui T, Buch S, Diergaarde B, Weissfeld LA, Grandis J, et al. Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent. Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2429–37. DOI: 10.1158/1055-9965.EPI-11-052010.1158/1055-9965.EPI-11-0520321090721890746]Search in Google Scholar
[50. An J, Liu Z, Hu Z, Li G, Wang L-E, Sturgis EM, et al. Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 2007 Aug 1;16(8):1633–8 DOI: 10.1158/1055-9965.EPI-07-025210.1158/1055-9965.EPI-07-025217684138]Search in Google Scholar
[51. Sun Y, Tan L, Li H, Qin X, Liu J. Association of NER pathway gene polymorphisms with susceptibility to laryngeal cancer in a Chinese population. Int J Clin Exp Pathol. 2015 Sep 1;8(9):11615–21.]Search in Google Scholar